
    
      Design: Open-label, block-randomised, comparative, multicentric trial. Setting: Four primary
      care health facilities, two in urban and two in rural areas of Madang and East Sepik
      Province, Papua New Guinea.

      Participants: Patients of all ages with recurrent uncomplicated malaria Intervention: Random
      assignment to receive either Cotrifazid, mefloquine or the standard treatment of
      quinine+sulfadoxine/pyrimethamine (SP).

      Outcome measures: Incidence of clinical and laboratory adverse events; rate of clinical
      and/or parasitological failure at day 14
    
  